0001121702FALSE00011217022024-02-222024-02-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 
Date of Report (Date of earliest event reported) February 22, 2024
 
YIELD10 BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
 

Delaware001-3313304-3158289
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
19 Presidential Way, Woburn, Massachusetts
 01801
(Address of principal executive offices)(Zip Code)
 
Registrant’s Telephone Number, Including Area Code: (617) 583-1700 
N/A 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per shareYTEN
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o





Item 4.01 Changes in Registrant's Certifying Accountant.
On February 22, 2024, the Audit Committee of the Board of Directors of Yield10 Bioscience, Inc. (the “Company”) approved the appointment of Berkowitz Pollack Brant Advisors +CPAs, LLP (“BPB”) as the Company’s new independent registered public accounting firm, effective immediately.
During the fiscal years ended December 31, 2022 and 2021, the Company did not consult with BPB with regard to (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and no written report was provided to the Company or oral advice provided to the Company by BPB that BPB concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (b) any matter that was subject to any disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  YIELD10 BIOSCIENCE, INC.
   
February 26, 2024By:/s/ Oliver P. Peoples
  Oliver P. Peoples
  President & Chief Executive Officer


v3.24.0.1
Cover
Feb. 22, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 22, 2024
Entity Registrant Name YIELD10 BIOSCIENCE, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-33133
Entity Tax Identification Number 04-3158289
Entity Address, Address Line One 19 Presidential Way
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code 617
Local Phone Number 583-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Central Index Key 0001121702
Amendment Flag false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol YTEN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Yield10 Bioscience Charts.
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Yield10 Bioscience Charts.